FAP targeting using FAP-based radiolabeled tracers allows the delivery of radionuclides carrying either imaging photons and/or ionizing particles (α and β+/β−) directly to tumor stroma, resulting in nuclear imaging and/or radionuclide therapy of FAP-positive tumors. The gene discussed is FAP; the disease is neoplasm.